Synthaverse S.A.: Business Overview, Financials & Competitive Analysis
Synthaverse S.A. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Established niche pharma player with specialized oncology products facing near-term profitability challenges amid modest valuation. Synthaverse operates in a specialized pharmaceutical niche with established products and international reach, but demonstrates financial challenges with recent quarterly losses and modest market capitalization. The company's historic immunotherapy expertise provides competitive advantage, though recent.
What is Synthaverse S.A.'s industry? Synthaverse S.A. (synthaverse.com) operates in Pharmaceuticals & Biotechnology. AskCyborg classifies Synthaverse S.A. under Pharmaceuticals & Biotechnology in its company registry.
Synthaverse S.A. is a pharmaceutical company that manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. The company is a Po...
Cyborg Score thesis
Established niche pharma player with specialized oncology products facing near-term profitability challenges amid modest...
Read the full analyst-debate transcript →Get the Latest Synthaverse S.A. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeSynthaverse S.A. Overview
Pro stress-test →Synthaverse S.A. is a pharmaceutical company that manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. The company is a Polish pharmaceutical firm with almost 100 years of tradition.
Strategic Profile
Pro stress-test →The company specializes in oncological immunotherapy products such as OnkoBCG 50 and 100 for treating superficial and non-invasive bladder tumors, as well as immunoglobulin and vaccine products. Synthaverse manufactures one of the few drugs used internationally in the oncological immunotherapy of bladder cancer.
Competitive Landscape
Pro stress-test →Synthaverse operates in the specialized pharmaceuticals segment with particular strength in oncological immunotherapy for bladder cancer treatment. The company competes against larger multinational pharmaceutical firms and specialized biotech companies, but its narrow focus on BCG immunotherapy and established products provides some differentiation.
Industry Context
Synthaverse S.A. operates in Pharmaceuticals & Biotechnology.
Key facts
Founded: 1944 · Headquarters: Lublin, Poland · Revenue: $13.9M · Market cap: $79.8M